CN104918483B - 生成及使用经遗传修饰的非人动物的方法 - Google Patents

生成及使用经遗传修饰的非人动物的方法 Download PDF

Info

Publication number
CN104918483B
CN104918483B CN201380056429.6A CN201380056429A CN104918483B CN 104918483 B CN104918483 B CN 104918483B CN 201380056429 A CN201380056429 A CN 201380056429A CN 104918483 B CN104918483 B CN 104918483B
Authority
CN
China
Prior art keywords
human
nucleic acid
cells
promoter
human animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380056429.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104918483A (zh
Inventor
R·弗拉维尔
T·施特罗维希
M·G·曼茨
C·博尔索蒂
M·多达普卡
A·J·墨菲
S·史蒂文斯
G·D·雅克波罗斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for Research in Biomedicine IRB
Yale University
Regeneron Pharmaceuticals Inc
Original Assignee
Institute for Research in Biomedicine IRB
Yale University
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute for Research in Biomedicine IRB, Yale University, Regeneron Pharmaceuticals Inc filed Critical Institute for Research in Biomedicine IRB
Priority to CN202210388378.8A priority Critical patent/CN114766432B/zh
Priority to CN201810319216.2A priority patent/CN108401987B/zh
Publication of CN104918483A publication Critical patent/CN104918483A/zh
Application granted granted Critical
Publication of CN104918483B publication Critical patent/CN104918483B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C12N2015/8572—Animal models for proliferative diseases, e.g. comprising an oncogene

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Environmental Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201380056429.6A 2012-11-05 2013-11-05 生成及使用经遗传修饰的非人动物的方法 Active CN104918483B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202210388378.8A CN114766432B (zh) 2012-11-05 2013-11-05 经遗传修饰的非人动物及其使用方法
CN201810319216.2A CN108401987B (zh) 2012-11-05 2013-11-05 经遗传修饰的非人动物及其使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261722437P 2012-11-05 2012-11-05
US61/722,437 2012-11-05
PCT/US2013/068569 WO2014071397A2 (en) 2012-11-05 2013-11-05 Genetically modified non-human animals and methods of use thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202210388378.8A Division CN114766432B (zh) 2012-11-05 2013-11-05 经遗传修饰的非人动物及其使用方法
CN201810319216.2A Division CN108401987B (zh) 2012-11-05 2013-11-05 经遗传修饰的非人动物及其使用方法

Publications (2)

Publication Number Publication Date
CN104918483A CN104918483A (zh) 2015-09-16
CN104918483B true CN104918483B (zh) 2018-05-11

Family

ID=49876957

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202210388378.8A Active CN114766432B (zh) 2012-11-05 2013-11-05 经遗传修饰的非人动物及其使用方法
CN201380056429.6A Active CN104918483B (zh) 2012-11-05 2013-11-05 生成及使用经遗传修饰的非人动物的方法
CN201810319216.2A Active CN108401987B (zh) 2012-11-05 2013-11-05 经遗传修饰的非人动物及其使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202210388378.8A Active CN114766432B (zh) 2012-11-05 2013-11-05 经遗传修饰的非人动物及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810319216.2A Active CN108401987B (zh) 2012-11-05 2013-11-05 经遗传修饰的非人动物及其使用方法

Country Status (19)

Country Link
US (5) US9901082B2 (enExample)
EP (5) EP4389764A3 (enExample)
JP (5) JP6422441B2 (enExample)
KR (5) KR102649893B1 (enExample)
CN (3) CN114766432B (enExample)
AU (3) AU2013337242B2 (enExample)
CA (1) CA2887706C (enExample)
DK (4) DK3939423T3 (enExample)
ES (4) ES2748662T3 (enExample)
FI (1) FI3939423T3 (enExample)
IL (5) IL311744B2 (enExample)
MX (3) MX370856B (enExample)
MY (1) MY175400A (enExample)
NO (1) NO2946162T3 (enExample)
NZ (3) NZ724353A (enExample)
PT (4) PT3939423T (enExample)
RU (1) RU2673156C2 (enExample)
SG (2) SG10201707449TA (enExample)
WO (1) WO2014071397A2 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
ES2908587T3 (es) 2009-10-06 2022-05-03 Regeneron Pharma Ratones modificados genéticamente e injerto
PT4233537T (pt) 2011-02-15 2025-09-08 Regeneron Pharma Ratinhos humanizados para m-csf e utilizações dos mesmos
RU2642319C2 (ru) * 2012-09-07 2018-01-24 Йель Юниверсити Генетически модифицированные, не принадлежащие к человеческому роду животные и способ их использования
PT3939423T (pt) 2012-11-05 2024-05-29 Regeneron Pharma Animais não humanos geneticamente modificados e métodos de utilização dos mesmos
EP3543253B1 (en) 2013-02-20 2024-03-27 Regeneron Pharmaceuticals, Inc. Mice expressing humanized t-cell co-receptors
HRP20181866T1 (hr) 2013-02-22 2019-01-25 Regeneron Pharmaceuticals, Inc. Miševi koji izražavaju humanizirane komplekse glavne histokompatibilnosti
KR102407354B1 (ko) 2013-09-23 2022-06-10 리제너론 파마슈티칼스 인코포레이티드 인간화된 신호-조절 단백질 유전자를 가지는 비-인간 동물
SI3138397T1 (sl) 2013-10-15 2019-04-30 Regeneron Pharmaceuticals, Inc. Humanizirane živali IL-15
US20150143558A1 (en) 2013-11-19 2015-05-21 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
MX358206B (es) 2013-11-19 2018-08-09 Regeneron Pharma Animales no humanos que tienen un gen humanizado de un ligando inductor de la proliferacion.
DK3129400T3 (da) 2014-04-08 2020-06-08 Regeneron Pharma Ikke-humane dyr med humaniserede Fc-gamma-receptorer
CN111647627A (zh) 2014-04-28 2020-09-11 重组股份有限公司 多重基因编辑
US9795121B2 (en) 2014-05-05 2017-10-24 Regeneron Pharmaceuticals, Inc. Humanized C3 animals
NO2785538T3 (enExample) 2014-05-07 2018-08-04
MX379268B (es) * 2014-05-19 2025-03-11 Regeneron Pharma Animales no humanos geneticamente modificados que expresan eritropoyetina de humano.
SMT202000184T1 (it) 2014-06-19 2020-05-08 Regeneron Pharma Animali non umani aventi un gene 1 della morte cellulare programmata umanizzato
EP3223605B9 (en) 2014-11-24 2021-08-18 Regeneron Pharmaceuticals, Inc. Non-human animals expressing humanized cd3 complex
HUE064960T2 (hu) * 2014-12-05 2024-04-28 Regeneron Pharma Differenciációs 47 gén humanizált klasztert tartalmazó nem-humán állatok
AU2015360667B2 (en) 2014-12-09 2021-09-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 274 gene
WO2016137841A1 (en) * 2015-02-26 2016-09-01 William Paterson University Of New Jersey Transgenic mice
WO2016164492A2 (en) 2015-04-06 2016-10-13 Regeneron Pharmaceuticals, Inc. Humanized t cell mediated immune responses in non-human animals
CN107896479B (zh) * 2015-04-13 2021-07-13 再生元制药公司 人源化SIRPα-IL15敲入小鼠及其使用方法
EP3376857B1 (en) 2015-11-20 2021-02-24 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized lymphocyte-activation gene 3
PT3422845T (pt) 2016-02-29 2021-08-26 Regeneron Pharma Roedores com um gene tmprss humanizado
KR20190038613A (ko) * 2016-08-11 2019-04-08 더 잭슨 래보라토리 유전자 변형된 면역결핍 비-인간 동물에서의 개선된 인간 적혈구 생존에 관한 방법 및 조성물
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
JP7458185B2 (ja) * 2016-11-30 2024-03-29 ザ ジャクソン ラボラトリー 改善されたヒト自然免疫細胞の発生を有するヒト化マウスモデル
CA3053386A1 (en) * 2017-02-27 2018-08-30 Regeneron Pharmaceuticals, Inc. Non-human animal models of retinoschisis
CN107115424B (zh) * 2017-05-09 2018-05-29 江西樟树市正康医药生物科技有限公司 改变酸性体质保钙及清热解毒的中药组合物及制备方法
JP7129426B2 (ja) 2017-05-12 2022-09-01 ザ ジャクソン ラボラトリー Ｍｈｃクラスｉおよびｍｈｃクラスｉｉを欠損しているｎｓｇマウス
EP4276185A3 (en) 2017-09-29 2024-02-21 Regeneron Pharmaceuticals, Inc. Rodents comprising a humanized ttr locus and methods of use
US11712026B2 (en) 2017-10-18 2023-08-01 The Jackson Laboratory Murine-MHC-deficient HLA-transgenic nod-mouse models for T1D therapy development
CN111655031B (zh) 2017-11-30 2022-11-18 瑞泽恩制药公司 包含人源化trkb基因座的非人动物
MA52091A (fr) 2018-03-21 2021-01-27 Alx Oncology Inc Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation
IL314733A (en) 2018-03-26 2024-10-01 Regeneron Pharma Humanized rodents for testing therapeutic agents
US11589562B2 (en) 2018-07-16 2023-02-28 Regeneran Pharmaceuticals, Inc. Mouse model of DITRA disease and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN111057721B (zh) * 2018-10-12 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化IL-4和/或IL-4Rα改造动物模型的制备方法及应用
CN111172190B (zh) * 2018-12-25 2021-07-30 百奥赛图江苏基因生物技术有限公司 人源化细胞因子csf2基因改造非人动物的构建方法及应用
IL286905B2 (en) 2019-04-04 2024-06-01 Regeneron Pharma Non-human animals containing the human coagulation factor 12 locus
KR20220016869A (ko) 2019-06-04 2022-02-10 리제너론 파마슈티칼스 인코포레이티드 베타-슬립 돌연변이를 갖는 인간화 ttr 좌위를 포함하는 비-인간 동물 및 사용 방법
BR112021022722A2 (pt) 2019-06-07 2022-01-04 Regeneron Pharma Animal não humano, célula de animal não humana, genoma de animal não humano, gene de albumina animal não humana humanizada, vetor de alvejamento, método de avaliação da atividade de um reagente, e, método de otimização da atividade de um reagente
US20220354098A1 (en) * 2019-07-17 2022-11-10 Yale University Genetically Modified Non-Human Animals and Methods of Use Thereof
CN111304246B (zh) * 2019-12-17 2021-05-04 百奥赛图江苏基因生物技术有限公司 一种人源化细胞因子动物模型、制备方法及应用
JP7600245B2 (ja) * 2020-01-10 2024-12-16 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド ヒト又はキメラｍｈｃタンパク質複合体を有する遺伝子組換え非ヒト動物
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
EP4216971A4 (en) 2020-09-24 2024-10-02 The Jackson Laboratory HUMANIZED MOUSE MODELS FOR EVALUATING CELLULAR IMMUNOTHERAPY
CN118511853A (zh) 2021-03-31 2024-08-20 瑞泽恩制药公司 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠
CN116918767A (zh) * 2022-04-07 2023-10-24 上海立迪生物技术股份有限公司 一种人all小鼠原位pdox模型的建立方法及应用
CN116918766A (zh) * 2022-04-07 2023-10-24 上海立迪生物技术股份有限公司 一种人aml小鼠原位pdox模型的建立方法及应用
WO2024020057A1 (en) 2022-07-19 2024-01-25 Regeneron Pharmaceuticals, Inc. Genetically modified animal model and its use to model the human immune system
AU2024304358A1 (en) 2023-06-16 2025-11-06 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
US20250255282A1 (en) 2024-02-08 2025-08-14 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
WO2025212991A1 (en) 2024-04-05 2025-10-09 Regeneron Pharmaceuticals, Inc. Rodent models of disease
WO2025250495A1 (en) * 2024-05-28 2025-12-04 Regeneron Pharmaceuticals, Inc. Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039232A2 (en) * 2001-10-26 2003-05-15 Large Scale Biology Corporation Endothelial cell derived hemotopoietic growth factor
WO2011044050A2 (en) * 2009-10-06 2011-04-14 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
WO2012040207A2 (en) * 2010-09-20 2012-03-29 Yale University HUMAM SIRPAα TRANSGENIC ANIMALS AND THEIR METHODS OF USE
WO2012112544A2 (en) * 2011-02-15 2012-08-23 Regeneron Pharmaceuticals, Inc. Humanized m-csf mice
CN102725400A (zh) * 2009-06-29 2012-10-10 麻省理工学院 制造人源化的非人类哺乳动物的方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5573930A (en) 1985-02-05 1996-11-12 Cetus Oncology Corporation DNA encoding various forms of colony stimulating factor-1
WO1988003173A2 (en) 1986-10-24 1988-05-05 Cetus Corporation New forms of colony stimulating factor-1
EP0322240B1 (en) 1987-12-23 1995-03-01 The Board Of Trustees Of The Leland Stanford Junior University Chimeric immunocompromised mammals and their use
JP2981486B2 (ja) 1988-06-14 1999-11-22 メディカル・バイオロジー・インスティチュート 哺乳動物の免疫系研究方法
JP2935511B2 (ja) * 1989-10-20 1999-08-16 忠三 岸本 ヒトｉｌ―６レセプターの製造方法
US5849288A (en) 1990-01-15 1998-12-15 Yeda Research And Development Co. Ltd. Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells
US5652373A (en) 1990-01-15 1997-07-29 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
DK0438053T3 (da) 1990-01-15 1999-11-22 Yeda Res & Dev Varig transplantation og udvikling af humane hæmopoietiske cellelinjer i normale pattedyr
AU637914B2 (en) 1990-05-03 1993-06-10 Systemix, Inc. Human lymphoid tissue in an immunocompromised host
US5633426A (en) 1990-05-25 1997-05-27 Systemix, Inc. In vivo use of human bone marrow for investigation and production
EP0484512A4 (en) 1990-05-25 1993-05-05 Systemix, Inc. Human peripheral blood cells in an immunocompromised host
US5222982A (en) 1991-02-11 1993-06-29 Ommaya Ayub K Spinal fluid driven artificial organ
EP0571525A1 (en) 1991-02-11 1993-12-01 OMMAYA, Ayub K. Spinal fluid driven artificial organ
EP0517199A1 (en) 1991-06-04 1992-12-09 Yeda Research And Development Company, Ltd. Durable engraftment of human tissue and cells in normal mammals
WO1993005796A1 (en) 1991-09-19 1993-04-01 The Scripps Research Institute Method for producing human antibodies in a non-human animal, and animals therefor
DE69229254T2 (de) 1991-10-30 1999-09-23 Idemitsu Kosan Co. Ltd., Tokio/Tokyo Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper
US6353150B1 (en) 1991-11-22 2002-03-05 Hsc Research And Development Limited Partnership Chimeric mammals with human hematopoietic cells
WO1993018144A1 (en) 1992-03-05 1993-09-16 The Trustees Of Columbia University Of The City Of New York Recombination activating gene deficient animal
US5866757A (en) 1992-06-02 1999-02-02 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
US6018096A (en) 1993-05-03 2000-01-25 Surrogen, Inc. Animal model for engraftment, proliferation and differentiation of human hematopoietic stem cells
CA2103693A1 (en) 1993-08-06 1995-02-07 Steven Gallinger Animal model of the human immune system
CA2195678A1 (en) 1994-07-27 1996-02-08 Joseph A. Borkowski Bradykinin b2 receptor modified transgenic non-human animals
US6455756B1 (en) 1994-08-12 2002-09-24 Novartis Ag Long term xenogeneic myeloid and lymphoid cell production in chimeric immunocompromised mice
US7273753B2 (en) 1996-08-02 2007-09-25 Center Of Blood Research Purification and uses of dendritic cells and monocytes
US6248721B1 (en) 1997-04-09 2001-06-19 Lung-Ji Chang Method of using mouse model for evaluation of HIV vaccines
CA2284689C (en) 1997-04-09 2009-10-06 Lung-Ji Chang Animal model for evaluation of vaccines
GB2337755B (en) * 1998-05-29 2003-10-29 Secr Defence Virus vaccine
WO2001015521A1 (en) 1999-08-31 2001-03-08 Genencor International, Inc. Transgenic mammal capable of facilitating production of donor-specific functional immunity
US20030028911A1 (en) 1999-08-31 2003-02-06 Manley Huang Transgenic mammal capable of facilitating production of donor-specific functional immunity
CA2392740A1 (en) * 1999-12-09 2001-06-14 Human Genome Sciences, Inc. Il-6 like polynucleotides, polypeptides, and antibodies
US6864061B2 (en) 2000-09-14 2005-03-08 Genetrol Biotherapeutics, Inc. Method for screening compounds for anti-inflammatory activity
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
BR0211079A (pt) * 2001-07-10 2005-08-30 Johnson & Johnson Res Pty Ltd Processos para a modificação genética de células hematopoiéticas progenitoras e empregos das células modificadas
EP1994824A1 (en) 2001-11-15 2008-11-26 Kirin Pharma Kabushiki Kaisha Chimeric non-human animal
WO2004005496A1 (ja) 2002-07-05 2004-01-15 Kirin Beer Kabushiki Kaisha 臍帯血、骨髄、末梢血等に含まれる新規な未分化幹細胞集団
CN101250553A (zh) 2002-07-13 2008-08-27 上海医学遗传研究所 一种促人血小板生成素表达载体及其构建方法
AU2003278790A1 (en) 2002-09-09 2004-03-29 California Institute Of Technology Methods and compositions for the generation of humanized mice
EP1418185A1 (en) 2002-11-11 2004-05-12 Aventis Pharma Deutschland GmbH Use of EDG2 receptor in an animal model of heart failure
KR20050084317A (ko) 2002-12-16 2005-08-26 제넨테크, 인크. 인간 ｃｄ２０ 및(또는) ｃｄ１６을 발현하는 트랜스제닉마우스
CA2515288A1 (en) * 2003-03-12 2004-09-23 Genentech, Inc. Compositions with hematopoietic and immune activity
EP1598364A1 (en) * 2004-05-21 2005-11-23 AGIRx Limited Chimerical soluble hyper IL-11 receptor and use thereof
DK1802193T3 (da) 2004-10-19 2014-06-10 Regeneron Pharma Fremgangsmåde til frembringelse af en homozygot mus til genetisk modifikation
US7759541B2 (en) 2004-12-13 2010-07-20 Iti Life Sciences Transgenic animals for assessing drug metabolism and toxicity
GB2434578A (en) 2006-01-26 2007-08-01 Univ Basel Transgenic animals
PT2019683T (pt) 2006-04-25 2017-03-17 Univ California Administração de fatores de crescimento para o tratamento de distúrbios do snc
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
WO2008060360A2 (en) 2006-09-28 2008-05-22 Surmodics, Inc. Implantable medical device with apertures for delivery of bioactive agents
EP2088854A1 (en) 2006-12-05 2009-08-19 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Improved xenogenic immune system in a non-human mammal
JP5666903B2 (ja) 2007-05-23 2015-02-12 サンガモ バイオサイエンシーズ， インコーポレイテッド 導入遺伝子の発現を増強するための方法および組成物
GB0718029D0 (en) 2007-09-14 2007-10-24 Iti Scotland Ltd Two step cluster deletion and humanisation
WO2009042917A1 (en) 2007-09-28 2009-04-02 The General Hospital Corporation Methods and compositions for antibody production
WO2009097468A2 (en) 2008-01-29 2009-08-06 Kliman Gilbert H Drug delivery devices, kits and methods therefor
WO2010119039A1 (en) * 2009-04-13 2010-10-21 Apceth Gmbh & Co. Kg Engineered mesenchymal stem cells and method of using same to treat tumors
SG176117A1 (en) 2009-06-29 2011-12-29 Ilya B Leskov Non-human mammal model of human hematopoietic cancer
RU2425880C2 (ru) 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
SG10201408415PA (en) * 2009-12-21 2015-01-29 Regeneron Pharma HUMANIZED FCγ R MICE
WO2012051572A1 (en) 2010-10-15 2012-04-19 Massachusetts Institute Of Technology A humanized non-human mammal model of malaria and uses thereof
BR112014008529A2 (pt) * 2011-10-28 2017-04-18 Regeneron Pharma il-6 humanizado e receptor de il-6
RU2642319C2 (ru) 2012-09-07 2018-01-24 Йель Юниверсити Генетически модифицированные, не принадлежащие к человеческому роду животные и способ их использования
PT3939423T (pt) 2012-11-05 2024-05-29 Regeneron Pharma Animais não humanos geneticamente modificados e métodos de utilização dos mesmos
KR102407354B1 (ko) 2013-09-23 2022-06-10 리제너론 파마슈티칼스 인코포레이티드 인간화된 신호-조절 단백질 유전자를 가지는 비-인간 동물
SI3138397T1 (sl) 2013-10-15 2019-04-30 Regeneron Pharmaceuticals, Inc. Humanizirane živali IL-15
MX379268B (es) 2014-05-19 2025-03-11 Regeneron Pharma Animales no humanos geneticamente modificados que expresan eritropoyetina de humano.
CN107896479B (zh) 2015-04-13 2021-07-13 再生元制药公司 人源化SIRPα-IL15敲入小鼠及其使用方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039232A2 (en) * 2001-10-26 2003-05-15 Large Scale Biology Corporation Endothelial cell derived hemotopoietic growth factor
CN102725400A (zh) * 2009-06-29 2012-10-10 麻省理工学院 制造人源化的非人类哺乳动物的方法
WO2011044050A2 (en) * 2009-10-06 2011-04-14 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
WO2012040207A2 (en) * 2010-09-20 2012-03-29 Yale University HUMAM SIRPAα TRANSGENIC ANIMALS AND THEIR METHODS OF USE
WO2012112544A2 (en) * 2011-02-15 2012-08-23 Regeneron Pharmaceuticals, Inc. Humanized m-csf mice

Also Published As

Publication number Publication date
JP7579304B2 (ja) 2024-11-07
IL299887B2 (en) 2024-09-01
NO2946162T3 (enExample) 2018-06-09
DK3308641T3 (da) 2019-10-07
KR20240042142A (ko) 2024-04-01
CN104918483A (zh) 2015-09-16
JP7105844B2 (ja) 2022-07-25
KR20220075242A (ko) 2022-06-07
NZ631614A (en) 2016-10-28
AU2022200302B2 (en) 2025-04-10
IL270124B1 (enExample) 2023-02-01
WO2014071397A2 (en) 2014-05-08
KR102458016B1 (ko) 2022-10-25
IL238478B (en) 2018-05-31
MX2015005654A (es) 2016-04-28
IL311744B1 (en) 2025-06-01
CA2887706C (en) 2022-08-02
KR20210087567A (ko) 2021-07-12
EP3308641A1 (en) 2018-04-18
US20180049413A1 (en) 2018-02-22
IL258968A (en) 2018-06-28
IL311744B2 (en) 2025-10-01
IL258968B (en) 2019-10-31
CN114766432B (zh) 2024-08-02
KR20150081285A (ko) 2015-07-13
KR20220148307A (ko) 2022-11-04
MX2020012427A (es) 2022-06-08
EP3556206A1 (en) 2019-10-23
JP2015534819A (ja) 2015-12-07
EP3939423A1 (en) 2022-01-19
EP3308641B1 (en) 2019-07-03
US20240099278A1 (en) 2024-03-28
IL311744A (en) 2024-05-01
CN108401987B (zh) 2022-04-29
IL270124B2 (en) 2023-06-01
ES2983031T3 (es) 2024-10-21
EP2914102A2 (en) 2015-09-09
PT3939423T (pt) 2024-05-29
US11778995B2 (en) 2023-10-10
KR102275412B1 (ko) 2021-07-12
CA2887706A1 (en) 2014-05-08
US20160366862A1 (en) 2016-12-22
EP4389764A3 (en) 2024-08-14
DK2914102T3 (en) 2017-12-11
PT3556206T (pt) 2021-08-24
ES2748662T3 (es) 2020-03-17
CN108401987A (zh) 2018-08-17
KR102768101B1 (ko) 2025-02-18
US9986724B2 (en) 2018-06-05
RU2015121195A (ru) 2016-12-27
AU2013337242A1 (en) 2015-04-30
NZ724353A (en) 2022-05-27
AU2019204775B2 (en) 2021-10-21
HK1210380A1 (en) 2016-04-22
IL238478A0 (en) 2015-06-30
PT3308641T (pt) 2019-10-24
JP2019037238A (ja) 2019-03-14
JP6772234B2 (ja) 2020-10-21
ES2884598T3 (es) 2021-12-10
WO2014071397A3 (en) 2014-06-26
JP2025010204A (ja) 2025-01-20
JP6422441B2 (ja) 2018-11-14
RU2018140189A (ru) 2018-12-10
IL299887B1 (en) 2024-05-01
KR102402806B1 (ko) 2022-05-30
EP3939423B1 (en) 2024-03-06
NZ749626A (en) 2023-11-24
AU2013337242B2 (en) 2019-04-04
DK3556206T3 (da) 2021-08-09
MY175400A (en) 2020-06-24
IL270124A (enExample) 2019-12-31
EP3556206B1 (en) 2021-06-02
US20210100228A1 (en) 2021-04-08
RU2018140189A3 (enExample) 2022-05-04
MX370856B (es) 2020-01-08
FI3939423T3 (fi) 2024-05-23
IL299887A (en) 2023-03-01
CN114766432A (zh) 2022-07-22
EP2914102B1 (en) 2017-10-18
US9901082B2 (en) 2018-02-27
SG11201502685XA (en) 2015-05-28
DK3939423T3 (da) 2024-05-06
JP2022132376A (ja) 2022-09-08
MX377561B (es) 2025-03-10
HK1253909A1 (en) 2019-07-05
AU2019204775A1 (en) 2019-07-25
MX2019015882A (es) 2020-02-07
ES2655442T3 (es) 2018-02-20
RU2673156C2 (ru) 2018-11-22
US20140134662A1 (en) 2014-05-15
PT2914102T (pt) 2018-01-15
SG10201707449TA (en) 2017-10-30
AU2022200302A1 (en) 2022-02-10
EP4389764A2 (en) 2024-06-26
JP2021010371A (ja) 2021-02-04
KR102649893B1 (ko) 2024-03-25
US10785968B2 (en) 2020-09-29

Similar Documents

Publication Publication Date Title
JP7579304B2 (ja) 遺伝学的に修飾された非ヒト動物およびその使用法
HK40111833A (en) Genetically modified non-human animals and methods of use thereof
HK40068456B (en) Genetically modified non-human animals and methods of use thereof
HK40068456A (en) Genetically modified non-human animals and methods of use thereof
HK40016315A (en) Genetically modified non-human animals and methods of use thereof
HK40016315B (en) Genetically modified non-human animals and methods of use thereof
HK1253909B (en) Immunodeficient, genetically modified rodent and methods of use thereof
HK1210380B (en) Genetically modified non-human animals and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant